603658 安图生物
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入992,202-0.37%4,226,4134,471,2034,443,6564,441,627
减:营业总成本758,2541.58%3,171,0183,307,1503,214,9603,278,389
    其中:营业成本330,993-4.85%1,452,3011,546,5741,559,7131,783,657
               财务费用8,063221.36%9,3931,6798,788(2,041)
               资产减值损失1,700321.86%(19,709)(62,954)(32,692)(35,777)
公允价值变动收益1,20184.81%(3,496)3,610580--
投资收益19,877-15.23%104,50792,272129,381118,585
    其中:对联营企业和合营企业的投资收益(45)-97.04%(1,430)(6,261)(3,369)2,000
营业利润262,754-13.43%1,217,9291,245,4891,365,7481,296,382
利润总额261,987-13.29%1,222,7661,289,0561,362,5441,293,715
减:所得税费用22,849-21.37%136,38289,823138,413105,033
净利润239,137-12.43%1,086,3841,199,2331,224,1311,188,682
减:非控股权益2,690-15.93%18,3684,7816,69221,245
股东净利润236,447-12.39%1,068,0161,194,4521,217,4391,167,437

市场价值指针
每股收益 (元) *0.410-12.77%1.8702.0702.1002.000
每股派息 (元) *----1.3101.2601.0520.800
每股净资产 (元) *16.0343.22%15.621--14.55913.275
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容